Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jinjing Xia
Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients
PLoS ONE
Multidisciplinary
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Clinical Cancer Research
Cancer Research
Oncology
How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Clinicopathological Features and Clinical Efficacy of Crizotinib in Chinese Patients With ROS1‑positive Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Clinical Efficacy and Safety of Afatinib in the Treatment of Non-Small-Cell Lung Cancer in Chinese Patients
OncoTargets and Therapy
Oncology
Pharmacology
Budget Impact of Alectinib in the Treatment of Naïve Anaplastic Lymphoma Kinase-Positive (ALK+) Advanced Non-Small Cell Lung Cancer (NSCLC) in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Alectinib in ALK -Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial
The Lancet Oncology
Oncology
